HUTCHMED (China) Limited (HCM)
Develops cancer and immune disease drugs for global markets, primarily in Asia and the US
$11.21+0.01%Healthcare
StockGlow Score
Neutral
BearishBullish
1 year ago-35.1%
The outlook
HCM is trading near the bottom of its 52-week range at $11.21, with analyst consensus showing a "Buy" rating and an average price target roughly double the current price. The stock's price trend is mixed relative to its moving averages, and it trades at a low trailing P/E of 4.2, suggesting a deeply discounted valuation.
What’s behind the score
Analyst consensusBuy — 1.6 avg of 14 analysts
Price trendMixed vs its moving averages
52-week range15% of the way from its 52-week low to high
Price targetAvg target +101% vs current price
Analyst price target
~12-month · 14 analysts$22.48average target+100.5% vs now
Now $11.21
Low $13.60High $40.40
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$1.93B
52-wk high
$19.50
52-wk low
$9.77
50-day avg
$11.14
200-day avg
$13.66
Trailing P/E
4.2